Literature DB >> 16716201

The molecular genetics of cognition: dopamine, COMT and BDNF.

J Savitz1, M Solms, R Ramesar.   

Abstract

The important contribution of genetic factors to the development of cognition and intelligence is widely acknowledged, but identification of these genes has proven to be difficult. Given a variety of evidence implicating the prefrontal cortex and its dopaminergic circuits in cognition, most of the research conducted to date has focused on genes regulating dopaminergic function. Here we review the genetic association studies carried out on catechol-O-methyltransferase (COMT) and the dopamine receptor genes, D1, D2 and D4. In addition, the evidence implicating another promising candidate gene, brain-derived neurotrophic factor (BDNF) in neuropsychological function, is assessed. Both the COMT val158met polymorphism and the BDNF val66met variant appear to influence cognitive function, but the specific neurocognitive processes involved continue to be a matter of debate. Part of the difficulty is distinguishing between false positives, pleiotropy and the influence of a general intelligence factor, g. Also at issue is the complexity of the relevant neuromolecular pathways, which make the inference of simple causal relationships difficult. The implications of molecular genetic cognitive research for psychiatry are discussed in light of these data.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16716201     DOI: 10.1111/j.1601-183X.2005.00163.x

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  95 in total

1.  Effect of Bcl-2 rs956572 SNP on regional gray matter volumes and cognitive function in elderly males without dementia.

Authors:  Mu-En Liu; Chu-Chung Huang; Jen-Ping Hwang; Albert C Yang; Pei-Chi Tu; Heng-Liang Yeh; Chen-Jee Hong; Ying-Jay Liou; Jin-Fan Chen; Ching-Po Lin; Shih-Jen Tsai
Journal:  Age (Dordr)       Date:  2011-12-25

Review 2.  Candidate mechanisms for chemotherapy-induced cognitive changes.

Authors:  Tim A Ahles; Andrew J Saykin
Journal:  Nat Rev Cancer       Date:  2007-03       Impact factor: 60.716

3.  A neurogenetics approach to defining differential susceptibility to institutional care.

Authors:  Zoe H Brett; Margaret Sheridan; Kate Humphreys; Anna Smyke; Mary Margaret Gleason; Nathan Fox; Charles Zeanah; Charles Nelson; Stacy Drury
Journal:  Int J Behav Dev       Date:  2015-03

4.  COMT influences on prefrontal and striatal blood oxygenation level-dependent responses during working memory among individuals with schizophrenia, their siblings, and healthy controls.

Authors:  Alan Ceaser; John G Csernansky; Deanna M Barch
Journal:  Cogn Neuropsychiatry       Date:  2012-10-03       Impact factor: 1.871

5.  Impact of interacting functional variants in COMT on regional gray matter volume in human brain.

Authors:  Robyn Honea; Beth A Verchinski; Lukas Pezawas; Bhaskar S Kolachana; Joseph H Callicott; Venkata S Mattay; Daniel R Weinberger; Andreas Meyer-Lindenberg
Journal:  Neuroimage       Date:  2008-11-21       Impact factor: 6.556

Review 6.  Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.

Authors:  Anthony O Ahmed; Ishrat A Bhat
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

Review 7.  Preventing neurocognitive late effects in childhood cancer survivors.

Authors:  Martha A Askins; Bartlett D Moore
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

8.  The COMT Val158Met polymorphism and cognition in depressed and nondepressed older adults.

Authors:  G G Potter; W D Taylor; D R McQuoid; D C Steffens; K A Welsh-Bohmer; K R R Krishnan
Journal:  Int J Geriatr Psychiatry       Date:  2009-10       Impact factor: 3.485

9.  Genetics of Sleep Timing, Duration and Homeostasis in Humans.

Authors:  Namni Goel
Journal:  Sleep Med Clin       Date:  2011-06-03

Review 10.  Genes, cognition and brain through a COMT lens.

Authors:  D Dickinson; B Elvevåg
Journal:  Neuroscience       Date:  2009-05-13       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.